查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1233127

2023-2030 年按類型（簡單仿製藥、特種仿製藥、生物仿製藥）、給藥途徑、產品、應用、分銷渠道、地區和細分市場預測的仿製藥市場規模、份額和趨勢分析報告

Generic Pharmaceuticals Market Size, Share & Trends Analysis Report By Type (Simple Generics, Specialty Generics, Biosimilars), By Route Of Administration, By Product, By Application, By Distribution Channel, By Region & Segment Forecasts, 2023-2030
出版日期: | 出版商: Grand View Research | 英文 220 Pages | 商品交期: 2-10個工作天內

價格

仿製藥市場的增長和趨勢

Grand View Research, Inc. 的最新研究預測，從 2023 年到 2030 年，全球仿製藥市場將以 8.3% 的複合年增長率增長，達到超過 6829 億美元的增長。

仿製藥市場的增長在很大程度上是由即將到期的產品專利推動的，這為仿製藥和生物仿製藥製造商將其產品推向市場開闢了道路。 例如，2020 年 7 月，Teva Pharmaceutical Industries Ltd. 與 Takeda Pharmaceutical Company Limited 成立了一家合資企業，以製造和商業化專業資產、複雜仿製藥和其他管線。 該合資企業有望推動仿製藥市場。

此外，政府正在加大推廣仿製藥的力度，以降低藥品總成本，導致關鍵產品的專利到期。 例如，澳大利亞治療機構 (TGA) 的目標是為其公民提供負擔得起、高效、優質且易於獲得的仿製藥。 為了支持仿製藥，TGA 致力於減少仿製藥的監管環境和報銷負擔，並通過與製造商的國際合作將仿製藥推向市場來減少壁壘。 澳大利亞政府的此類舉措為市場開闢了新途徑。

在美國，每年有數百萬美國人使用仿製藥進行治療，仿製藥仍然是醫療保健系統的最佳價值，並且通常被稱為“患者保護和醫療保健成本”。考慮到最近醫療改革法的製定，如《負擔調整法》的出台，我們可以期待仿製藥的普及。 特等書 111-148。 法律要求政府規定的處方藥承保範圍是這些新健康保險計劃的一部分。 此類政策的出台可以提高醫療保健的質量和效率，並促進市場增長。

傳染性和非傳染性疾病的負擔不斷增加，易患糖尿病和高血壓等慢性病的老齡化人口增加，可能對市場增長產生積極影響。 根據發表的文章，截至 2022 年 9 月，全球每年將有大約 1790 萬普通公民患有心血管疾病 (CVD)。 結核病、糖尿病、心血管疾病和艾滋病毒等疾病是導致死亡的主要原因。 這些疾病的發病率和流行率不斷增加，預計將推動市場。

仿製藥市場報告亮點

  • 按類型劃分，小分子部分預計到 2022 年將佔據最大份額，達到 91.2%，而大分子部分預計將以最快的速度增長。 生物仿製藥的批准和採用的增加預計將推動大分子領域的增長。
  • 在給藥途徑方面，注射劑增長最快，因為生物仿製藥正在獲得批准。
  • 按應用劃分，心血管疾病在 2022 年佔市場份額的 18.27%。 這是由於仿製藥他汀類藥物的最高處方率，以及高疾病負擔。
  • 由於投資增加以及製藥公司專注於開發高附加值產品，預計特種仿製藥將溫和增長。 2019年美國FDA批准了110個聯合仿製藥。
  • 從分銷渠道來看，零售藥店細分市場將在 2022 年主導市場空間。 世界各地的零售藥店連鎖店都在投資先進技術，並採取新舉措來提高銷售額並吸引更多顧客。
  • 到 2022 年，北美將佔據大部分市場份額。 積極的政府舉措和不斷發展的藥品報銷環境支持持續增長。

內容

第一章調查方法及範圍

  • 市場細分
  • 調查方法
  • 信息採購
    • 購買的數據庫
    • GVR 內部數據庫
    • 次要信息
    • 初步調查
    • 初步調查的內容
  • 信息或數據分析
    • 數據分析模型
  • 市場製定和驗證
  • 模型詳細信息
    • 商品流分析
      • 方法 1：商品流方法
      • 方法 2：使用自下而上的方法逐個國家/地區進行市場估算
  • 全球市場：CAGR 計算
  • 調查假設
  • 二級信息列表
  • 主要信息列表
  • 初步調查分析
    • 市場情景
    • 主要 KoL 回復
  • 目的
  • 縮寫列表

第 2 章執行摘要

  • 市場概況
  • 片段快照
  • 競爭快照

第 3 章市場變量、趨勢和範圍

  • 描繪滲透率和增長前景
  • 監管狀況
  • SWOT 分析，按因素（政治和法律、經濟、技術）
  • 波特的五力分析
  • 用戶視角分析
  • 仿製藥市場動態
    • 市場驅動因素分析
      • 生物製品和小分子專利到期
      • 增加 ANDA 批准並推出仿製藥
      • 政府為推廣仿製藥的使用所做的努力
      • 不斷增加的疾病負擔和不斷增長的老年人口
    • 市場製約因素分析
      • 價格壓力

第 4 章仿製藥市場 - 細分分析，按類型，2018-2030（十億美元）

  • 仿製藥市場：類型差異分析
  • 簡單泛型
  • 特殊通用
  • 生物仿製藥

第 5 章仿製藥市場 - 細分分析，按應用，2018-2030（十億美元）

  • 仿製藥市場：應用變化分析
  • 中樞神經系統疾病
  • 呼吸系統疾病
  • 激素和相關疾病
  • 消化系統疾病
  • 心血管疾病
  • 感染
  • 癌症
  • 糖尿病
  • 其他

第 6 章仿製藥市場 - 細分分析，副產品，2018-2030（十億美元）

  • 仿製藥市場：產品差異分析
  • 小分子
  • 聚合物

第 7 章仿製藥市場 - 細分分析，按給藥途徑，2018-2030 年（十億美元）

  • 仿製藥市場：給藥途徑變化分析
  • 口語
  • 可注射
  • 可吸入
  • 其他

第 8 章仿製藥市場 - 細分分析，按分銷渠道，2018-2030 年（十億美元）

  • 仿製藥市場：分銷渠道變化分析
  • 醫院藥房
  • 零售藥房
  • 在線藥店

第 9 章仿製藥市場 - 細分分析，按地區，2018-2030（十億美元）

  • 仿製藥市場，按地區劃分的市場份額，2022 年和 2030 年
  • 北美
    • SWOT 分析
    • 美國
      • 主要國家動態
      • 目標疾病的患病率
      • 競爭場景
      • 監管框架
      • 贖回場景
    • 加拿大
      • 主要國家動態
      • 目標疾病的患病率
      • 競爭場景
      • 監管框架
      • 贖回場景
  • 歐洲
    • SWOT 分析：
    • 德國
      • 主要國家動態
      • 目標疾病的患病率
      • 競爭場景
      • 監管框架
      • 贖回場景
    • 英國
      • 主要國家動態
      • 目標疾病的患病率
      • 競爭場景
      • 監管框架
      • 贖回場景
    • 法國
      • 主要國家動態
      • 目標疾病的患病率
      • 競爭場景
      • 監管框架
      • 贖回場景
    • 意大利
      • 主要國家動態
      • 目標疾病的患病率
      • 競爭場景
      • 監管框架
      • 贖回場景
    • 西班牙
      • 主要國家動態
      • 目標疾病的患病率
      • 競爭場景
      • 監管框架
      • 贖回場景
    • 丹麥
      • 主要國家動態
      • 目標疾病的患病率
      • 競爭場景
      • 監管框架
      • 贖回場景
    • 瑞典
      • 主要國家動態
      • 目標疾病的患病率
      • 競爭場景
      • 監管框架
      • 贖回場景
    • 挪威
      • 主要國家動態
      • 目標疾病的患病率
      • 競爭場景
      • 監管框架
      • 贖回場景
  • 亞太地區
    • SWOT 分析：
    • 日本
      • 主要國家動態
      • 目標疾病的患病率
      • 競爭場景
      • 監管框架
      • 贖回場景
    • 中國
      • 主要國家動態
      • 目標疾病的患病率
      • 競爭場景
      • 監管框架
      • 贖回場景
    • 印度
      • 主要國家動態
      • 目標疾病的患病率
      • 競爭場景
      • 監管框架
      • 贖回場景
    • 澳大利亞
      • 主要國家動態
      • 目標疾病的患病率
      • 競爭場景
      • 監管框架和贖回方案
    • 泰國
      • 主要國家動態
      • 目標疾病的患病率
      • 競爭場景
      • 監管框架和贖回方案
    • 韓國
      • 主要國家動態
      • 目標疾病的患病率
      • 競爭場景
      • 監管框架和贖回方案
  • 拉丁美洲
    • SWOT 分析：
    • 巴西
      • 主要國家動態
      • 目標疾病的患病率
      • 競爭場景
      • 監管框架
      • 贖回場景
    • 墨西哥
      • 主要國家動態
      • 目標疾病的患病率
      • 競爭場景
      • 監管框架
      • 贖回場景
    • 阿根廷
      • 主要國家動態
      • 目標疾病的患病率
      • 競爭場景
      • 監管框架
      • 贖回場景
  • 中東和非洲 (MEA)
    • SWOT 分析：
    • 南非
      • 主要國家動態
      • 目標疾病的患病率
      • 競爭場景
      • 監管框架
      • 贖回場景
    • 沙特阿拉伯
      • 主要國家動態
      • 目標疾病的患病率
      • 競爭場景
      • 監管框架
      • 贖回場景
    • 阿拉伯聯合酋長國
      • 主要國家動態
      • 目標疾病的患病率
      • 競爭場景
      • 監管框架
      • 贖回場景
    • 科威特
      • 主要國家動態
      • 目標疾病的患病率
      • 競爭場景
      • 監管框架
      • 贖回場景

第 10 章仿製藥市場 - 競爭分析

  • 主要市場進入者的近期趨勢和影響分析
    • 新產品發布
    • 併購
    • 許可協議
    • 會議和活動
  • 公司分類
    • 創新者
    • 市場領導者
  • 供應商情況
    • 主要分銷商和渠道合作夥伴列表
    • 主要客戶
  • 上市公司
    • 2022 年主要參與者的市場份額分析
    • 企業市場分析
    • 熱圖分析
    • 競爭儀錶盤分析
      • 市場差異化因素
  • 私人公司
    • 主要初創公司名單
    • 本地網絡地圖
  • 公司簡介
    • Teva Pharmaceutical Industries Ltd
      • Company overview
      • Financial performance
      • Product benchmarking
      • Strategic initiatives
    • Viatris Inc.)
      • Company overview
      • Financial performance
      • Product benchmarking
      • Strategic initiatives
    • Sun Pharmaceutical Industries Ltd.
      • Company overview
      • Financial performance
      • Product benchmarking
      • Strategic initiatives
    • LUPIN
      • Company overview
      • Financial performance
      • Product benchmarking
      • Strategic initiatives
    • Novartis AG
      • Company overview
      • Sandoz International GmbH
      • Financial performance
      • Product benchmarking
      • Strategic initiatives
    • Allergan
      • Company overview
      • Financial performance
      • Product benchmarking
      • Strategic initiatives
    • AstraZeneca
      • Company overview
      • Financial performance
      • Product benchmarking
      • Strategic initiatives
    • Sawai Pharmaceutical Co., Ltd.
      • Company overview
      • Financial performance
      • Product benchmarking
      • Strategic initiatives
    • Hikma Pharmaceuticals PLC
      • Company overview
      • Financial performance
      • Product benchmarking
      • Strategic initiatives
    • Dr. Reddy's Laboratories Ltd.
      • Company overview
      • Financial performance
      • Product benchmarking
      • Strategic initiatives
    • Cipla Inc.
      • Company overview
      • Financial performance
      • Product benchmarking
      • Strategic initiatives
    • Sanofi
      • Company overview
      • Financial performance
      • Product benchmarking
      • Strategic initiatives
    • Aurobindo Pharma
      • Company overview
      • Financial performance
      • Product benchmarking
      • Strategic initiatives
    • Endo International plc
      • Company overview
      • Financial performance
      • Product benchmarking
      • Strategic initiatives
Product Code: GVR-4-68040-031-8

Generic Pharmaceuticals Market Growth & Trends:

The global generic pharmaceuticals market is expected to reach over USD 682.9 billion expanding at a CAGR of 8.3% from 2023 to 2030, according to a new study by Grand View Research, Inc. The growth of the generic pharmaceuticals market is largely attributable to the expiry of product patents which clears the way for generic drugs and biosimilar manufacturers to launch products in the market. For instance, in July 2020, Teva Pharmaceutical Industries Ltd. entered into a joint venture with Takeda Pharmaceutical Company Limited aimed to manufacture and commercialize specialty assets, complex generic drugs, and other pipeline opportunities. This joint venture was anticipated to drive the generic pharmaceuticals market.

Furthermore, increasing government initiatives to promote generic drug products for reducing the overall healthcare expenditure on pharmaceuticals and the patent expiry of major products. For instance, the Therapeutic Goods Administration (TGA) Australia aims to offer affordable, efficient, high-quality, and accessible generic drugs to citizens for their treatment. In support of generic drugs, the TGA has been trying to reduce regulatory and reimbursement burdens such as changing the landscape of generic drugs and reducing barriers through international collaboration with manufacturers to launch their generic drugs in the market. Such initiatives of the Australian government open new avenues in the market.

In the U.S., every year millions of Americans use a generic drug for their treatment, hence, generic drugs remain the best bargain in the health care insurance programs, and given the recent enactment of healthcare reform legislation such as the introduction of the Patient Protection and Affordable Health Care Act. P.L. 111-148. Under this act, prescription drug coverage is mandated by the government as part of these new health insurance plans. The introduction of such policies may improve the quality and efficiency of healthcare, thereby, driving market growth.

The rising disease burden of infectious & non-infectious diseases coupled with the increasing geriatric population which is prone to chronic diseases such as diabetes, and hypertension, among others, may positively affect the market growth. According to an article published, in September 2022, around 17.9 million general population suffer from cardiovascular diseases (CVD) every year worldwide. Diseases including TB, diabetes, cardiovascular diseases, and HIV were among the major causes of death. The increasing incidence and prevalence of these diseases is expected to drive the market.

Generic Pharmaceuticals Market Report Highlights:

  • The small molecule segment by type held the largest share of 91.2% in 2022 and the large molecule segment is expected to grow at the fastest rate. The increasing approval and uptake of biosimilars is expected to drive the growth of the large molecule segment.
  • Based on the route of administration, the injectable segment is the fastest-growing segment due to the rising approval for biosimilar drugs.
  • By application, cardiovascular diseases dominated the market with a share of 18.27% in 2022, owing to the highest prescription rate of generic statins coupled with a high disease burden.
  • Specialty generics are expected to grow moderately due to increasing investments and the focus of pharmaceutical companies to develop value-added products. In 2019, the U.S. FDA approved 110 complex generics.
  • Based on distribution channel, the retail pharmacy segment dominated the market space in 2022. Retail pharmacy chains across the world are investing in advanced technologies and undertaking new initiatives to improve sales and attract more customers.
  • North America held the majority share in 2022. Favorable government initiatives coupled with an evolving reimbursement landscape for pharmaceutical products support continual growth.

Table of Contents

Chapter 1 Methodology and Scope

  • 1.1 Market segmentation
    • 1.1.1 Estimates and Forecast Timeline
  • 1.2 Research Methodology
  • 1.3 Information Procurement
    • 1.3.1 Purchased Database
    • 1.3.2 GVR's Internal Database
    • 1.3.3 Secondary Sources
    • 1.3.4 Primary Research
    • 1.3.5 Details of Primary Research
  • 1.4 Information or Data Analysis
    • 1.4.1 Data Analysis Models
  • 1.5 Market Formulation & Validation
  • 1.6 Model Details
    • 1.6.1 Commodity Flow Analysis
      • 1.6.1.1 Approach 1: Commodity Flow Approach
      • 1.6.1.2 Approach 2: Country-wise market estimation using bottom-up approach
  • 1.7 Global Market: CAGR Calculation
  • 1.8 Research Assumptions
  • 1.9 List of Secondary Sources
  • 1.10 List of Primary Sources
  • 1.11 Primary Research Analysis
    • 1.11.1 Market scenario
    • 1.11.2 Key KoL responses
  • 1.12 Objectives
    • 1.12.1 Objective 1:
    • 1.12.2 Objective 2:
  • 1.13 List of Abbreviations

Chapter 2 Executive Summary

  • 2.1 Market Snapshot
  • 2.2 Segment Snapshot
  • 2.3 Competitive Snapshoty

Chapter 3 Market Variables, Trends & Scope

  • 3.1 Penetration and Growth Prospect Mapping
  • 3.2 Regulatory Landscape
  • 3.3 SWOT Analysis, By Factor (Political & Legal, Economic, and Technological)
  • 3.4 Porter's Five Forces Analysis
  • 3.5 User Perspective Analysis
  • 3.6 Generic Pharmaceuticals Market Dynamics
    • 3.6.1 Market Driver Analysis
      • 3.6.1.1 Patent expiry of biologics and small molecules
      • 3.6.1.2 Increasing ANDA approval and Generic Product Launches
      • 3.6.1.3 Government initiatives to promote usage of generics
      • 3.6.1.4 Increasing Disease Burden and Rising Geriatric Population
    • 3.6.2 Market Restraint Analysis
      • 3.6.2.1 Pricing Pressures

Chapter 4 Generic Pharmaceuticals Market - Segment Analysis, By Type, 2018 - 2030 (USD Billion)

  • 4.1 Generic Pharmaceuticals Market: Type Movement Analysis
  • 4.2 Simple Generics
    • 4.2.1 Simple Generics Market Estimates and Forecast, 2018 - 2030 (USD Billion)
  • 4.3 Specialty Generics
    • 4.3.1 Specialty Generics Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 4.4 Biosimilars
    • 4.4.1 Biosimilars Market Estimates and Forecasts, 2018 - 2030 (USD Billion)

Chapter 5 Generic Pharmaceuticals Market - Segment Analysis, By Application, 2018 - 2030 (USD Billion)

  • 5.1 Generic Pharmaceuticals Market: Application Movement Analysis
  • 5.2 Central Nervous System Disorders
    • 5.2.1 Central Nervous System Disorders Market Estimates and Forecast, 2018 - 2030 (USD Billion)
  • 5.3 Respiratory Diseases
    • 5.3.1 Respiratory Diseases Market Estimates and Forecast, 2018 - 2030 (USD Billion)
  • 5.4 Hormones and Related Diseases
    • 5.4.1 Hormones and Related Diseases Market Estimates and Forecast, 2018 - 2030 (USD Billion)
  • 5.5 Gastrointestinal Diseases
    • 5.5.1 Gastrointestinal Diseases Market Estimates and Forecast, 2018 - 2030 (USD Billion)
  • 5.6 Cardiovascular Diseases
    • 5.6.1 Cardiovascular Diseases Market Estimates and Forecast, 2018 - 2030 (USD Billion)
  • 5.7 Infectious Diseases
    • 5.7.1 Infectious Diseases Market Estimates and Forecast, 2018 - 2030 (USD Billion)
  • 5.8 Cancer
    • 5.8.1 Cancer Market Estimates and Forecast, 2018 - 2030 (USD Billion)
  • 5.9 Diabetes
    • 5.9.1 Diabetes Market Estimates and Forecast, 2018 - 2030 (USD Billion)
  • 5.10 Others
    • 5.10.1 Others Market Estimates and Forecast, 2018 - 2030 (USD Billion)

Chapter 6 Generic Pharmaceuticals Market - Segment Analysis, By Product, 2018 - 2030 (USD Billion)

  • 6.1 Generic Pharmaceuticals Market: Product Movement Analysis
  • 6.2 Small Molecule
    • 6.2.1 Small Molecule Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 6.3 Large Molecule
    • 6.3.1 Large molecule Market Estimates and Forecasts, 2018 - 2030 (USD Billion)

Chapter 7 Generic Pharmaceuticals Market - Segment Analysis, By Route of Administration, 2018 - 2030 (USD Billion)

  • 7.1 Generic Pharmaceuticals Market: Route of Administration Movement Analysis
  • 7.2 Oral
    • 7.2.1 Oral Market Estimates and Forecast, 2018 - 2030 (USD Billion)
  • 7.3 Injectable
    • 7.3.1 Injectable Market Estimates and Forecast, 2018 - 2030 (USD Billion)
  • 7.4 Inhalable
    • 7.4.1 Inhalable Market Estimates and Forecast, 2018 - 2030 (USD Billion)
  • 7.5 Others
    • 7.5.1 Others Market Estimates and Forecast, 2018 - 2030 (USD Billion)

Chapter 8 Generic Pharmaceuticals Market - Segment Analysis, By Distribution Channel, 2018 - 2030 (USD Billion)

  • 8.1 Generic Pharmaceuticals Market: Distribution Channel Movement Analysis
  • 8.2 Hospital Pharmacy
    • 8.2.1 Hospital Pharmacy Market Estimates and Forecast, 2018 - 2030 (USD Billion)
  • 8.3 Retail Pharmacy
    • 8.3.1 Retail Pharmacy Market Estimates and Forecast, 2018 - 2030 (USD Billion)
  • 8.4 Online Pharmacy
    • 8.4.1 Online Pharmacy Market Estimates and Forecast, 2018 - 2030 (USD Billion)

Chapter 9 Generic Pharmaceuticals Market - Segment Analysis, By Region, 2018 - 2030 (USD Billion)

  • 9.1 Generic Pharmaceuticals Market, Market Share by Region, 2022 & 2030
  • 9.2 North America
    • 9.2.1 SWOT Analysis
      • 9.2.1.1 North America Generic Pharmaceutical Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 9.2.2 U.S.
      • 9.2.2.1 Key Country Dynamics
      • 9.2.2.2 Target Disease Prevalence
      • 9.2.2.3 Competitive Scenario
      • 9.2.2.4 Regulatory Framework
      • 9.2.2.5 Reimbursement Scenario
      • 9.2.2.6 U.S. Generic Pharmaceutical Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 9.2.3 Canada
      • 9.2.3.1 Key Country Dynamics
      • 9.2.3.2 Target Disease Prevalence
      • 9.2.3.3 Competitive Scenario
      • 9.2.3.4 Regulatory Framework
      • 9.2.3.5 Reimbursement Scenario
      • 9.2.3.6 Canada Generic Pharmaceutical Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 9.2 Europe
    • 9.2.1 SWOT Analysis:
      • 9.2.1.1 Europe Generic Pharmaceutical Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 9.2.2 Germany
      • 9.2.2.1 Key Country Dynamics
      • 9.2.2.2 Target Disease Prevalence
      • 9.2.2.3 Competitive Scenario
      • 9.2.2.4 Regulatory Framework
      • 9.2.2.5 Reimbursement Scenario
      • 9.2.2.6 Germany Generic Pharmaceutical Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 9.2.3 U.K.
      • 9.2.3.1 Key Country Dynamics
      • 9.2.3.2 Target Disease Prevalence
      • 9.2.3.3 Competitive Scenario
      • 9.2.3.4 Regulatory Framework
      • 9.2.3.5 Reimbursement Scenario
      • 9.2.3.6 UK Generic Pharmaceutical Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 9.2.4 France
      • 9.2.4.1 Key Country Dynamics
      • 9.2.4.2 Target Disease Prevalence
      • 9.2.4.3 Competitive Scenario
      • 9.2.4.4 Regulatory Framework
      • 9.2.4.5 Reimbursement Scenario
      • 9.2.4.6 France Generic Pharmaceutical Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 9.2.5 Italy
      • 9.2.5.1 Key Country Dynamics
      • 9.2.5.2 Target Disease Prevalence
      • 9.2.5.3 Competitive Scenario
      • 9.2.5.4 Regulatory Framework
      • 9.2.5.5 Reimbursement Scenario
      • 9.2.5.6 Italy Generic Pharmaceutical Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 9.2.6 Spain
      • 9.2.6.1 Key Country Dynamics
      • 9.2.6.2 Target Disease Prevalence
      • 9.2.6.3 Competitive Scenario
      • 9.2.6.4 Regulatory Framework
      • 9.2.6.5 Reimbursement Scenario
      • 9.2.6.6 Spain Generic Pharmaceutical Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 9.2.7 Denmark
      • 9.2.7.1 Key Country Dynamics
      • 9.2.7.2 Target Disease Prevalence
      • 9.2.7.3 Competitive Scenario
      • 9.2.7.4 Regulatory Framework
      • 9.2.7.5 Reimbursement Scenario
      • 9.2.7.6 Denmark Generic Pharmaceutical Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 9.2.8 Sweden
      • 9.2.8.1 Key Country Dynamics
      • 9.2.8.2 Target Disease Prevalence
      • 9.2.8.3 Competitive Scenario
      • 9.2.8.4 Regulatory Framework
      • 9.2.8.5 Reimbursement Scenario
      • 9.2.8.6 Sweden Generic Pharmaceutical Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 9.2.9 Norway
      • 9.2.9.1 Key Country Dynamics
      • 9.2.9.2 Target Disease Prevalence
      • 9.2.9.3 Competitive Scenario
      • 9.2.9.4 Regulatory Framework
      • 9.2.9.5 Reimbursement Scenario
      • 9.2.9.6 Norway Generic Pharmaceutical Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
      • 9.2.9.7 Rest of Europe Generic Pharmaceutical Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 9.3 Asia Pacific
    • 9.3.1 SWOT Analysis:
      • 9.3.1.1 Asia Pacific Generic Pharmaceutical Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 9.3.2 Japan
      • 9.3.2.1 Key Country Dynamics
      • 9.3.2.2 Target Disease Prevalence
      • 9.3.2.3 Competitive Scenario
      • 9.3.2.4 Regulatory Framework
      • 9.3.2.5 Reimbursement Scenario
      • 9.3.2.6 Japan Generic Pharmaceutical Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 9.3.3 China
      • 9.3.3.1 Key Country Dynamics
      • 9.3.3.2 Target Disease Prevalence
      • 9.3.3.3 Competitive Scenario
      • 9.3.3.4 Regulatory Framework
      • 9.3.3.5 Reimbursement Scenario
      • 9.3.3.6 China Generic Pharmaceutical Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 9.3.4 India
      • 9.3.4.1 Key Country Dynamics
      • 9.3.4.2 Target Disease Prevalence
      • 9.3.4.3 Competitive Scenario
      • 9.3.4.4 Regulatory Framework
      • 9.3.4.5 Reimbursement Scenario
      • 9.3.4.6 India Generic Pharmaceutical Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 9.3.5 Australia
      • 9.3.5.1 Key Country Dynamics
      • 9.3.5.2 Target Disease Prevalence
      • 9.3.5.3 Competitive Scenario
      • 9.3.5.4 Regulatory Framework & Reimbursement Scenario
      • 9.3.5.5 Australia Generic Pharmaceutical Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 9.3.6 Thailand
      • 9.3.6.1 Key Country Dynamics
      • 9.3.6.2 Target Disease Prevalence
      • 9.3.6.3 Competitive Scenario
      • 9.3.6.4 Regulatory Framework & Reimbursement Scenario
      • 9.3.6.5 Thailand Generic Pharmaceutical Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 9.3.7 South Korea
      • 9.3.7.1 Key Country Dynamics
      • 9.3.7.2 Target Disease Prevalence
      • 9.3.7.3 Competitive Scenario
      • 9.3.7.4 Regulatory Framework & Reimbursement Scenario
      • 9.3.7.5 South Korea Generic Pharmaceutical Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
      • 9.3.7.6 Rest of Asia Pacific Generic Pharmaceutical Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 9.4 Latin America
    • 9.4.1 SWOT Analysis:
      • 9.4.1.1 Latin America Generic Pharmaceutical market estimates and forecasts, 2018 - 2030 (USD Billion)
    • 9.4.2 Brazil
      • 9.4.2.1 Key Country Dynamics
      • 9.4.2.2 Target Disease Prevalence
      • 9.4.2.3 Competitive Scenario
      • 9.4.2.4 Regulatory Framework
      • 9.4.2.5 Reimbursement Scenario
      • 9.4.2.6 Brazil Generic Pharmaceutical Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 9.4.3 Mexico
      • 9.4.3.1 Key Country Dynamics
      • 9.4.3.2 Target Disease Prevalence
      • 9.4.3.3 Competitive Scenario
      • 9.4.3.4 Regulatory Framework
      • 9.4.3.5 Reimbursement Scenario
      • 9.4.3.6 Mexico Generic Pharmaceutical Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 9.4.4 Argentina
      • 9.4.4.1 Key Country Dynamics
      • 9.4.4.2 Target Disease Prevalence
      • 9.4.4.3 Competitive Scenario
      • 9.4.4.4 Regulatory Framework
      • 9.4.4.5 Reimbursement Scenario
      • 9.4.4.6 Argentina Generic Pharmaceutical Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
      • 9.4.4.7 Rest of Latin America Generic Pharmaceutical Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 9.5 Middle East & Africa (MEA)
    • 9.5.1 SWOT Analysis:
      • 9.5.1.1 Middle East & Africa Generic Pharmaceutical Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 9.5.2 South Africa
      • 9.5.2.1 Key Country Dynamics
      • 9.5.2.2 Target Disease Prevalence
      • 9.5.2.3 Competitive Scenario
      • 9.5.2.4 Regulatory Framework
      • 9.5.2.5 Reimbursement Scenario
      • 9.5.2.6 South Africa Generic Pharmaceutical Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 9.5.3 Saudi Arabia
      • 9.5.3.1 Key Country Dynamics
      • 9.5.3.2 Target Disease Prevalence
      • 9.5.3.3 Competitive Scenario
      • 9.5.3.4 Regulatory Framework
      • 9.5.3.5 Reimbursement Scenario
      • 9.5.3.6 Saudi Arabia Generic Pharmaceutical Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 9.5.4 UAE
      • 9.5.4.1 Key Country Dynamics
      • 9.5.4.2 Target Disease Prevalence
      • 9.5.4.3 Competitive Scenario
      • 9.5.4.4 Regulatory Framework
      • 9.5.4.5 Reimbursement Scenario
      • 9.5.4.6 UAE Generic Pharmaceutical Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 9.5.5 Kuwait
      • 9.5.5.1 Key Country Dynamics
      • 9.5.5.2 Target Disease Prevalence
      • 9.5.5.3 Competitive Scenario
      • 9.5.5.4 Regulatory Framework
      • 9.5.5.5 Reimbursement Scenario
      • 9.5.5.6 Kuwait Generic Pharmaceutical Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
      • 9.5.5.7 Rest of MEA Generic Pharmaceutical Market Estimates and Forecasts, 2018 - 2030 (USD Billion)

Chapter 10 Generic Pharmaceuticals Market - Competitive Analysis

  • 10.1 Recent Developments & Impact Analysis, by Key Market Participants
    • 10.1.1 New Product Launch
    • 10.1.2 Merger and Acquisition
    • 10.1.3 Licensing Agreements
    • 10.1.4 Conferences and Campaigns
  • 10.2 Company Categorization
    • 10.2.1 Innovators
    • 10.2.2 Market Leaders
  • 10.3 Vendor Landscape
    • 10.3.1 List of key distributors and channel partners
    • 10.3.2 Key customers
  • 10.4 Public Companies
    • 10.4.1 Key company market share analysis, 2022
    • 10.4.2 Company market position analysis
    • 10.4.3 Heat map analysis
    • 10.4.4 Competitive Dashboard Analysis
      • 10.4.4.1 Market Differentiators
  • 10.5 Private Companies
    • 10.5.1 List of key emerging companies
    • 10.5.2 Regional Network Map
  • 10.6 Company Profile
    • 10.6.1 Teva Pharmaceutical Industries Ltd
      • 10.6.1.1 Company overview
      • 10.6.1.2 Financial performance
      • 10.6.1.3 Product benchmarking
      • 10.6.1.4 Strategic initiatives
    • 10.6.2 Viatris Inc.)
      • 10.6.2.1 Company overview
      • 10.6.2.2 Financial performance
      • 10.6.2.3 Product benchmarking
      • 10.6.2.4 Strategic initiatives
    • 10.6.3 Sun Pharmaceutical Industries Ltd.
      • 10.6.3.1 Company overview
      • 10.6.3.2 Financial performance
      • 10.6.3.3 Product benchmarking
      • 10.6.3.4 Strategic initiatives
    • 10.6.4 LUPIN
      • 10.6.4.1 Company overview
      • 10.6.4.2 Financial performance
      • 10.6.4.3 Product benchmarking
      • 10.6.4.4 Strategic initiatives
    • 10.6.5 Novartis AG
      • 10.6.5.1 Company overview
      • 10.6.5.2 Sandoz International GmbH
      • 10.6.5.3 Financial performance
      • 10.6.5.4 Product benchmarking
      • 10.6.5.5 Strategic initiatives
    • 10.6.6 Allergan
      • 10.6.6.1 Company overview
      • 10.6.6.2 Financial performance
      • 10.6.6.3 Product benchmarking
      • 10.6.6.4 Strategic initiatives
    • 10.6.7 AstraZeneca
      • 10.6.7.1 Company overview
      • 10.6.7.2 Financial performance
      • 10.6.7.3 Product benchmarking
      • 10.6.7.4 Strategic initiatives
    • 10.6.8 Sawai Pharmaceutical Co., Ltd.
      • 10.6.8.1 Company overview
      • 10.6.8.2 Financial performance
      • 10.6.8.3 Product benchmarking
      • 10.6.8.4 Strategic initiatives
    • 10.6.9 Hikma Pharmaceuticals PLC
      • 10.6.9.1 Company overview
      • 10.6.9.2 Financial performance
      • 10.6.9.3 Product benchmarking
      • 10.6.9.4 Strategic initiatives
    • 10.6.10 Dr. Reddy's Laboratories Ltd.
      • 10.6.10.1 Company overview
      • 10.6.10.2 Financial performance
      • 10.6.10.3 Product benchmarking
      • 10.6.10.4 Strategic initiatives
    • 10.6.11 Cipla Inc.
      • 10.6.11.1 Company overview
      • 10.6.11.2 Financial performance
      • 10.6.11.3 Product benchmarking
      • 10.6.11.4 Strategic initiatives
    • 10.6.12 Sanofi
      • 10.6.12.1 Company overview
      • 10.6.12.2 Financial performance
      • 10.6.12.3 Product benchmarking
      • 10.6.12.4 Strategic initiatives
    • 10.6.13 Aurobindo Pharma
      • 10.6.13.1 Company overview
      • 10.6.13.2 Financial performance
      • 10.6.13.3 Product benchmarking
      • 10.6.13.4 Strategic initiatives
    • 10.6.14 Endo International plc
      • 10.6.14.1 Company overview
      • 10.6.14.2 Financial performance
      • 10.6.14.3 Product benchmarking
      • 10.6.14.4 Strategic initiatives

List of Tables

  • Table 1 List of secondary sources
  • Table 2 List of Abbreviation
  • Table 3 Regulatory framework
  • Table 4 Patent expiry
  • Table 5 First generic products
  • Table 6 Healthcare expenses on pharmaceuticals
  • Table 7 Complex generic approved by U.S.FDA (2019)
  • Table 8 Prevalence of GERD
  • Table 9 Estimated new cancer case statistics, 2022
  • Table 10 Total Glaucoma Cases (2020)
  • Table 11 First generic oral products approved in 2019
  • Table 12 Leading market players anticipated to witness highest growth
  • Table 13 List of key distributor
  • Table 14 North America Generic pharmaceuticals Market, By Type, 2018 - 2030 (USD Billion)
  • Table 15 North America Generic pharmaceuticals Market, By Application, 2018 - 2030 (USD Billion)
  • Table 16 North America Generic pharmaceuticals Market, By Product, 2018 - 2030 (USD Billion)
  • Table 17 North America Generic pharmaceuticals Market, By Route of Administration, 2018 - 2030 (USD Billion)
  • Table 18 North America Generic pharmaceuticals Market, By Distribution Channel, 2018 - 2030 (USD Billion)
  • Table 19 U.S. Generic pharmaceuticals Market, By Type, 2018 - 2030 (USD Billion)
  • Table 20 U.S. Generic pharmaceuticals Market, By Application, 2018 - 2030 (USD Billion)
  • Table 21 U.S. Generic pharmaceuticals Market, By Product, 2018 - 2030 (USD Billion)
  • Table 22 U.S. Generic pharmaceuticals Market, By Route of Administration, 2018 - 2030 (USD Billion)
  • Table 23 U.S. Generic pharmaceuticals Market, By Distribution Channel, 2018 - 2030 (USD Billion)
  • Table 24 Canada Generic pharmaceuticals Market, By Type, 2018 - 2030 (USD Billion)
  • Table 25 Canada Generic pharmaceuticals Market, By Application, 2018 - 2030 (USD Billion)
  • Table 26 Canada Generic pharmaceuticals Market, By Product, 2018 - 2030 (USD Billion)
  • Table 26 Canada Generic pharmaceuticals Market, By Route of Administration, 2018 - 2030 (USD Billion)
  • Table 27 Canada Generic pharmaceuticals Market, By Distribution Channel, 2018 - 2030 (USD Billion)
  • Table 28 Europe Generic pharmaceuticals Market, By Type, 2018 - 2030 (USD Billion)
  • Table 29 Europe Generic pharmaceuticals Market, By Application, 2018 - 2030 (USD Billion)
  • Table 29 Europe Generic pharmaceuticals Market, By Product, 2018 - 2030 (USD Billion)
  • Table 30 Europe Generic pharmaceuticals Market, By Route of Administration, 2018 - 2030 (USD Billion)
  • Table 31 Europe Generic pharmaceuticals Market, By Distribution Channel, 2018 - 2030 (USD Billion)
  • Table 32 U.K. Generic pharmaceuticals Market, By Type, 2018 - 2030 (USD Billion)
  • Table 33 U.K. Generic pharmaceuticals Market, By Application, 2018 - 2030 (USD Billion)
  • Table 34 U.K. Generic pharmaceuticals Market, By Product, 2018 - 2030 (USD Billion)
  • Table 35 U.K. Generic pharmaceuticals Market, By Route of Administration, 2018 - 2030 (USD Billion)
  • Table 36 U.K. Generic pharmaceuticals Market, By Distribution Channel, 2018 - 2030 (USD Billion)
  • Table 37 Germany Generic pharmaceuticals Market, By Type, 2018 - 2030 (USD Billion)
  • Table 38 Germany Generic pharmaceuticals Market, By Application, 2018 - 2030 (USD Billion)
  • Table 39 Germany Generic pharmaceuticals Market, By Product, 2018 - 2030 (USD Billion)
  • Table 40 Germany Generic pharmaceuticals Market, By Route of Administration, 2018 - 2030 (USD Billion)
  • Table 41 Germany Generic pharmaceuticals Market, By Distribution Channel, 2018 - 2030 (USD Billion)
  • Table 42 Italy Generic pharmaceuticals Market, By Type, 2018 - 2030 (USD Billion)
  • Table 43 Italy Generic pharmaceuticals Market, By Application, 2018 - 2030 (USD Billion)
  • Table 44 Italy Generic pharmaceuticals Market, By Product, 2018 - 2030 (USD Billion)
  • Table 45 Italy Generic pharmaceuticals Market, By Route of Administration, 2018 - 2030 (USD Billion)
  • Table 46 Italy Generic pharmaceuticals Market, By Distribution Channel, 2018 - 2030 (USD Billion)
  • Table 47 France Generic pharmaceuticals Market, By Type, 2018 - 2030 (USD Billion)
  • Table 48 France Generic pharmaceuticals Market, By Application, 2018 - 2030 (USD Billion)
  • Table 49 France Generic pharmaceuticals Market, By Product, 2018 - 2030 (USD Billion)
  • Table 50 France Generic pharmaceuticals Market, By Route of Administration, 2018 - 2030 (USD Billion)
  • Table 51 France Generic pharmaceuticals Market, By Distribution Channel, 2018 - 2030 (USD Billion)
  • Table 52 Spain Generic pharmaceuticals Market, By Type, 2018 - 2030 (USD Billion)
  • Table 53 Spain Generic pharmaceuticals Market, By Application, 2018 - 2030 (USD Billion)
  • Table 54 Spain Generic pharmaceuticals Market, By Product, 2018 - 2030 (USD Billion)
  • Table 55 Spain Generic pharmaceuticals Market, By Route of Administration, 2018 - 2030 (USD Billion)
  • Table 56 Spain Generic pharmaceuticals Market, By Distribution Channel, 2018 - 2030 (USD Billion)
  • Table 57 Denmark Generic pharmaceuticals Market, By Type, 2018 - 2030 (USD Billion)
  • Table 58 Denmark Generic pharmaceuticals Market, By Application, 2018 - 2030 (USD Billion)
  • Table 59 Denmark Generic pharmaceuticals Market, By Product, 2018 - 2030 (USD Billion)
  • Table 60 Denmark Generic pharmaceuticals Market, By Route of Administration, 2018 - 2030 (USD Billion)
  • Table 61 Denmark Generic pharmaceuticals Market, By Distribution Channel, 2018 - 2030 (USD Billion)
  • Table 62 Sweden Generic pharmaceuticals Market, By Type, 2018 - 2030 (USD Billion)
  • Table 63 Sweden Generic pharmaceuticals Market, By Application, 2018 - 2030 (USD Billion)
  • Table 64 Sweden Generic pharmaceuticals Market, By Product, 2018 - 2030 (USD Billion)
  • Table 65 Sweden Generic pharmaceuticals Market, By Route of Administration, 2018 - 2030 (USD Billion)
  • Table 66 Sweden Generic pharmaceuticals Market, By Distribution Channel, 2018 - 2030 (USD Billion)
  • Table 67 Norway Generic pharmaceuticals Market, By Type, 2018 - 2030 (USD Billion)
  • Table 68 Norway Generic pharmaceuticals Market, By Application, 2018 - 2030 (USD Billion)
  • Table 69 Norway Generic pharmaceuticals Market, By Product, 2018 - 2030 (USD Billion)
  • Table 70 Norway Generic pharmaceuticals Market, By Route of Administration, 2018 - 2030 (USD Billion)
  • Table 71 Norway Generic pharmaceuticals Market, By Distribution Channel, 2018 - 2030 (USD Billion)
  • Table 72 Asia Pacific Generic pharmaceuticals Market, By Type, 2018 - 2030 (USD Billion)
  • Table 73 Asia Pacific Generic pharmaceuticals Market, By Application, 2018 - 2030 (USD Billion)
  • Table 74 Asia Pacific Generic pharmaceuticals Market, By Product, 2018 - 2030 (USD Billion)
  • Table 75 Asia Pacific Generic pharmaceuticals Market, By Route of Administration, 2018 - 2030 (USD Billion)
  • Table 76 Asia Pacific Generic pharmaceuticals Market, By Distribution Channel, 2018 - 2030 (USD Billion)
  • Table 77 Japan Generic pharmaceuticals Market, By Type, 2018 - 2030 (USD Billion)
  • Table 78 Japan Generic pharmaceuticals Market, By Application, 2018 - 2030 (USD Billion)
  • Table 79 Japan Generic pharmaceuticals Market, By Product, 2018 - 2030 (USD Billion)
  • Table 80 Japan Generic pharmaceuticals Market, By Route of Administration, 2018 - 2030 (USD Billion)
  • Table 81 Japan Generic pharmaceuticals Market, By Distribution Channel, 2018 - 2030 (USD Billion)
  • Table 82 China Generic pharmaceuticals Market, By Type, 2018 - 2030 (USD Billion)
  • Table 83 China Generic pharmaceuticals Market, By Application, 2018 - 2030 (USD Billion)
  • Table 84 China Generic pharmaceuticals Market, By Product, 2018 - 2030 (USD Billion)
  • Table 85 China Generic pharmaceuticals Market, By Route of Administration, 2018 - 2030 (USD Billion)
  • Table 86 China Generic pharmaceuticals Market, By Distribution Channel, 2018 - 2030 (USD Billion)
  • Table 87 India Generic pharmaceuticals Market, By Type, 2018 - 2030 (USD Billion)
  • Table 88 India Generic pharmaceuticals Market, By Application, 2018 - 2030 (USD Billion)
  • Table 89 India Generic pharmaceuticals Market, By Product, 2018 - 2030 (USD Billion)
  • Table 90 India Generic pharmaceuticals Market, By Route of Administration, 2018 - 2030 (USD Billion)
  • Table 91 India Generic pharmaceuticals Market, By Distribution Channel, 2018 - 2030 (USD Billion)
  • Table 92 Australia Generic pharmaceuticals Market, By Type, 2018 - 2030 (USD Billion)
  • Table 93 Australia Generic pharmaceuticals Market, By Application, 2018 - 2030 (USD Billion)
  • Table 94 Australia Generic pharmaceuticals Market, By Product, 2018 - 2030 (USD Billion)
  • Table 95 Australia Generic pharmaceuticals Market, By Route of Administration, 2018 - 2030 (USD Billion)
  • Table 96 Australia Generic pharmaceuticals Market, By Distribution Channel, 2018 - 2030 (USD Billion)
  • Table 97 South Korea Generic pharmaceuticals Market, By Type, 2018 - 2030 (USD Billion)
  • Table 98 South Korea Generic pharmaceuticals Market, By Application, 2018 - 2030 (USD Billion)
  • Table 99 South Korea Generic pharmaceuticals Market, By Product, 2018 - 2030 (USD Billion)
  • Table 100 South Korea Generic pharmaceuticals Market, By Route of Administration, 2018 - 2030 (USD Billion)
  • Table 101 South Korea Generic pharmaceuticals Market, By Distribution Channel, 2018 - 2030 (USD Billion)
  • Table 102 Thailand Generic pharmaceuticals Market, By Type, 2018 - 2030 (USD Billion)
  • Table 103 Thailand Generic pharmaceuticals Market, By Application, 2018 - 2030 (USD Billion)
  • Table 104 Thailand Generic pharmaceuticals Market, By Product, 2018 - 2030 (USD Billion)
  • Table 105 Thailand Generic pharmaceuticals Market, By Route of Administration, 2018 - 2030 (USD Billion)
  • Table 106 Thailand Generic pharmaceuticals Market, By Distribution Channel, 2018 - 2030 (USD Billion)
  • Table 107 Latin America Generic pharmaceuticals Market, By Type, 2018 - 2030 (USD Billion)
  • Table 108 Latin America Generic pharmaceuticals Market, By Application, 2018 - 2030 (USD Billion)
  • Table 109 Latin America Generic pharmaceuticals Market, By Product, 2018 - 2030 (USD Billion)
  • Table 110 Latin America Generic pharmaceuticals Market, By Route of Administration, 2018 - 2030 (USD Billion)
  • Table 111 Latin America Generic pharmaceuticals Market, By Distribution Channel, 2018 - 2030 (USD Billion)
  • Table 112 Brazil Generic pharmaceuticals Market, By Type, 2018 - 2030 (USD Billion)
  • Table 113 Brazil Generic pharmaceuticals Market, By Application, 2018 - 2030 (USD Billion)
  • Table 114 Brazil Generic pharmaceuticals Market, By Product, 2018 - 2030 (USD Billion)
  • Table 115 Brazil Generic pharmaceuticals Market, By Route of Administration, 2018 - 2030 (USD Billion)
  • Table 116 Brazil Generic pharmaceuticals Market, By Distribution Channel, 2018 - 2030 (USD Billion)
  • Table 117 Mexico Generic pharmaceuticals Market, By Type, 2018 - 2030 (USD Billion)
  • Table 118 Mexico Generic pharmaceuticals Market, By Application, 2018 - 2030 (USD Billion)
  • Table 119 Mexico Generic pharmaceuticals Market, By Product, 2018 - 2030 (USD Billion)
  • Table 120 Mexico Generic pharmaceuticals Market, By Route of Administration, 2018 - 2030 (USD Billion)
  • Table 121 Mexico Generic pharmaceuticals Market, By Distribution Channel, 2018 - 2030 (USD Billion)
  • Table 122 Argentina Generic pharmaceuticals Market, By Type, 2018 - 2030 (USD Billion)
  • Table 123 Argentina Generic pharmaceuticals Market, By Application, 2018 - 2030 (USD Billion)
  • Table 124 Argentina Generic pharmaceuticals Market, By Product, 2018 - 2030 (USD Billion)
  • Table 125 Argentina Generic pharmaceuticals Market, By Route of Administration, 2018 - 2030 (USD Billion)
  • Table 126 Argentina Generic pharmaceuticals Market, By Distribution Channel, 2018 - 2030 (USD Billion)
  • Table 127 MEA Generic pharmaceuticals Market, By Type, 2018 - 2030 (USD Billion)
  • Table 128 MEA Generic pharmaceuticals Market, By Application, 2018 - 2030 (USD Billion)
  • Table 129 MEA Generic pharmaceuticals Market, By Product, 2018 - 2030 (USD Billion)
  • Table 130 MEA Generic pharmaceuticals Market, By Route of Administration, 2018 - 2030 (USD Billion)
  • Table 131 MEA Generic pharmaceuticals Market, By Distribution Channel, 2018 - 2030 (USD Billion)
  • Table 132 South Africa Generic pharmaceuticals Market, By Type, 2018 - 2030 (USD Billion)
  • Table 133 South Africa Generic pharmaceuticals Market, By Application, 2018 - 2030 (USD Billion)
  • Table 134 South Africa Generic pharmaceuticals Market, By Product, 2018 - 2030 (USD Billion)
  • Table 135 South Africa Generic pharmaceuticals Market, By Route of Administration, 2018 - 2030 (USD Billion)
  • Table 136 South Africa Generic pharmaceuticals Market, By Distribution Channel, 2018 - 2030 (USD Billion)
  • Table 137 Saudi Arabia Generic pharmaceuticals Market, By Type, 2018 - 2030 (USD Billion)
  • Table 138 Saudi Arabia Generic pharmaceuticals Market, By Application, 2018 - 2030 (USD Billion)
  • Table 139 Saudi Arabia Generic pharmaceuticals Market, By Product, 2018 - 2030 (USD Billion)
  • Table 140 Saudi Arabia Generic pharmaceuticals Market, By Route of Administration, 2018 - 2030 (USD Billion)
  • Table 141 Saudi Arabia Generic pharmaceuticals Market, By Distribution Channel, 2018 - 2030 (USD Billion)
  • Table 142 UAE Generic pharmaceuticals Market, By Type, 2018 - 2030 (USD Billion)
  • Table 143 UAE Generic pharmaceuticals Market, By Application, 2018 - 2030 (USD Billion)
  • Table 144 UAE Generic pharmaceuticals Market, By Product, 2018 - 2030 (USD Billion)
  • Table 145 UAE Generic pharmaceuticals Market, By Route of Administration, 2018 - 2030 (USD Billion)
  • Table 146 UAE Generic pharmaceuticals Market, By Distribution Channel, 2018 - 2030 (USD Billion)
  • Table 147 KUWAIT Generic pharmaceuticals Market, By Type, 2018 - 2030 (USD Billion)
  • Table 148 KUWAIT Generic pharmaceuticals Market, By Application, 2018 - 2030 (USD Billion)
  • Table 149 KUWAIT Generic pharmaceuticals Market, By Product, 2018 - 2030 (USD Billion)
  • Table 150 KUWAIT Generic pharmaceuticals Market, By Route of Administration, 2018 - 2030 (USD Billion)
  • Table 151 KUWAIT Generic pharmaceuticals Market, By Distribution Channel, 2018 - 2030 (USD Billion)

List of Figures

  • Fig. 1 Generic Pharmaceuticals market segmentation
  • Fig. 2 Market research process
  • Fig. 3 Data triangulation techniques
  • Fig. 4 Primary research pattern
  • Fig. 5 Market research approaches
  • Fig. 6 Value-chain-based sizing & forecasting
  • Fig. 7 QFD modeling for market share assessment
  • Fig. 8 Market formulation & validation
  • Fig. 9 Commodity Flow Analysis
  • Fig. 10 Generic Pharmaceuticals Market Snapshot
  • Fig. 11 Penetration and growth prospect mapping
  • Fig. 12 SWOT Analysis, By Factor (Political & Legal, Economic, and Technological)
  • Fig. 13 Porter's Five Forces Analysis
  • Fig. 14 User Perspective Analysis
  • Fig. 15 Generic Pharmaceuticals Market Driver Impact
  • Fig. 16 Disease burden of non-communicable diseases (in Million), in 2018
  • Fig. 17 Generic Pharmaceuticals Market Restraint Impact
  • Fig. 18 Generic Pharmaceuticals market: Type outlook and key takeaways
  • Fig. 19 Generic Pharmaceuticals market: Type movement analysis
  • Fig. 20 Simple generics market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig. 21 Specialty generics market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig. 22 Biosimilars Market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig. 23 Generic Pharmaceuticals market: Application outlook and key takeaways
  • Fig. 24 Generic Pharmaceuticals market: Application movement analysis
  • Fig. 25 Central nervous system disorders market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig. 26 Respiratory diseases market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig. 27 Hormones and related diseases market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig. 28 Gastrointestinal diseases market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig. 29 Cardiovascular diseases market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig. 30 Infectious diseases market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig. 31 Cancer market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig. 32 Diabetes market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig. 33 Others market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig. 34 Generic Pharmaceuticals market: Product outlook and key takeaways
  • Fig. 35 Generic Pharmaceuticals market: Product movement analysis
  • Fig. 36 Small molecule market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig. 37 Large molecule market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig. 38 Generic Pharmaceuticals Market: Route of Administration Outlook and Key Takeaways
  • Fig. 39 Generic Pharmaceuticals market: Route of administration movement analysis
  • Fig. 40 Oral market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig. 41 Injectable market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig. 42 Inhalable market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig. 43 Others market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig. 44 Generic Pharmaceuticals Market: Distribution Channel Outlook and Key Takeaways
  • Fig. 45 Generic Pharmaceuticals Market: Distribution Channel Movement Analysis
  • Fig. 46 Hospital pharmacy market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig. 47 Retail pharmacy market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig. 48 Online pharmacy market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig. 49 Regional marketplace: Key takeaways
  • Fig. 50 Regional outlook, 2020 & 2030
  • Fig. 51 North America
  • Fig. 52 North America. market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig. 53 U.S.
  • Fig. 54 U.S. market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig. 55 Canada
  • Fig. 56 Canada market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig. 57 Europe
  • Fig. 58 Europe market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig. 59 U.K.
  • Fig. 60 U.K. market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig. 61 Germany
  • Fig. 62 Germany market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig. 63 France
  • Fig. 64 France market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig. 65 Spain
  • Fig. 66 Spain market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig. 67 Italy
  • Fig. 68 Italy market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig. 69 Denmark
  • Fig. 70 Denmark market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig. 71 Sweden
  • Fig. 72 Sweden market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig. 73 Norway
  • Fig. 74 Norway market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig. 75 Asia-Pacific
  • Fig. 76 Asia-Pacific market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig. 77 Japan
  • Fig. 78 Japan market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig. 79 China
  • Fig. 80 China market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig. 81 India
  • Fig. 82 India market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig. 83 Australia
  • Fig. 84 Australia market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig. 85 South Korea
  • Fig. 86 South Korea market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig. 87 Thailand
  • Fig. 88 Thailand market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig. 89 Latin America
  • Fig. 90 Latin America market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig. 91 Brazil
  • Fig. 92 Brazil market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig. 93 Mexico
  • Fig. 94 Mexico market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig. 95 Argentina
  • Fig. 96 Argentina market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig. 97 Middle East & Africa
  • Fig. 98 MEA market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig. 99 South Africa
  • Fig. 100 South Africa market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig. 101 Saudi Arabia
  • Fig. 102 Saudi Arabia market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig. 103 UAE
  • Fig. 104 UAE market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig. 105 Kuwait
  • Fig. 106 Kuwait market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig. 107 Market position analysis
  • Fig. 108 Profit margin
  • Fig. 109 Heat map analysis
  • Fig. 110 Market differentiators
  • Fig. 111 Regional Network Map